CCRM, and its partners, will deliver on the promise to make Canada a global leader in Regenerative Medicine (RM) asset development and commercialization.
CCRM is the commercialization partner of OIRM and Medicine by Design:
The Ontario Institute for Regenerative Medicine (OIRM) is a coordinated network of scientific, industry and business leaders aimed at advancing world-leading stem cell research and its translation into improved health and economic growth for Ontarians across eight priority disease areas. OIRM will accomplish this by leveraging the scientific discoveries emerging from prominent research centres in Toronto, Ottawa, Hamilton and London and using its expertise in commercialization and clinical translation to create effective new treatments for these diseases. OIRM brings together more than 150 researchers across nine institutions, along with partners representing industry, the private sector, government and charitable/not-for-profit organizations. OIRM emerged from a partnership between the Ontario Stem Cell Initiative (OSCI) and CCRM.
Established July 28, 2015, Medicine by Design (MbD) is a regenerative medicine centre at the University of Toronto (U of T) that will design and manufacture molecules, cells, tissues and organs that can be used to treat degenerative diseases. Led by U of T professor Peter Zandstra, MbD is focusing in three areas—Cells by Design, Tissues by Design and Organs by Design—and will create regenerative medicine technologies that will advance promising discoveries of new and better treatments for Canadians and people around the world.
MbD is supported primarily by $114 million in federal funding from the government’s Canada First Research Excellence Fund, the largest grant awarded in U of T history. The centre is affiliated with more than 50 researchers and clinicians from the U of T and its partner hospitals, and will collaborate with academics, commercialization entities and the private sector. CCRM is the commercialization partner for MbD. Learn more here.
GE Healthcare is the anchor partner in the Centre for Advanced Therapeutic Cell Technologies
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges.
GE Healthcare Life Sciences helps researchers, pharmaceutical companies and clinicians to discover, make, and use new medicines and therapies. This is how we enable and accelerate precision medicine such as cell and gene therapies. These therapies are showing great promise for the future of patient care. At GE Healthcare Life Sciences, we strive to be at the forefront of this revolution by providing the right combination of customized tools, analytics, and support, while helping to optimize scale-out manufacturing technologies.
Together we hope to realize the promise of these revolutionary new medicines and bring them into mainstream clinical use.
- MaRS Discovery District (MaRS DD)
MaRS DD is an innovation centre connecting the worlds of science, business and capital with the goal of dramatically improving commercial outcomes for entrepreneurs. Located in the heart of Toronto and networked across Ontario, the MaRS Centre is the gateway to Canada’s largest concentration of scientific research, anchored by major teaching hospitals, universities, and research institutes, adjacent to leading financial institutions and surrounded by a creative urban community. MaRS is a member of the Ontario Network of Excellence.
MI takes the most promising breakthroughs from 17 of Toronto’s top universities and research institutes, and commercializes them. They bring together the scientists and inventors from these member institutions with investors who are looking for high-potential opportunities, especially in the biosciences and technology. MI is a Centre of Excellence for Commercialization and Research (CECR) and is located in MaRS Discovery District.
The McEwen Centre’s vision is to be a world-renowned centre for stem cell biology and regenerative medicine. To achieve this goal, the team of McEwen Investigators is working together to accelerate the development of more effective treatments for conditions such as heart disease, diabetes, respiratory disease and spinal cord injury. The McEwen Centre is based at the MaRS Centre/Toronto Medical Discovery Tower. The McEwen Centre was established at the University Health Network in 2003 with a generous donation from Rob and Cheryl McEwen, which they matched in 2006 with a second donation.
CGP is at the crossroads of the legal, medical and public policy fields. The CGP promotes prospective structuring and guidance for both research in genomic health sciences and its applications. Currently CGP's research covers five areas of genomics and policy: procreation and reproductive genetics, pediatric health, privacy, public health, and personalized medicine. These domains are approached using three guiding foundations: internationalization, policy development and knowledge transfer. CGP allows CCRM to be at the forefront of responsible governance.
- Stem Cell Network (SCN)
In pursuit of Canadian excellence and global leadership in applied stem cell research, the SCN supports cutting-edge projects that translate research discoveries into new and better treatments for millions of patients in Canada and around the world. More than 100 scientists, clinicians, engineers, and social scientists with international reputations work closely together within the Stem Cell Network to bring rigor and innovation to Canadian stem cell research. SCN is a Network of Centres of Excellence (NCE) and is located in Ottawa.